Physician profile
Robert Mcfarlane
NPI 1710980826
$1,841.60
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,451 · 2020: $274 · 2022: $117.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $1,001.28 | 2019-2020 | |
| Amgen INC. | $259.34 | 2019-2022 | |
| Pfizer INC. | $182.27 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $132.32 | 2019-2022 | |
| Amarin Pharma, INC. | $127.05 | 2019 | |
| Alnylam Pharmaceuticals INC. | $95.75 | 2020 | |
| Janssen Pharmaceuticals, INC | $15.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.20 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.42 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mcfarlane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.